tbuckley/cabot-search huggingface dataset:
Smart bioadhesives for wound healing and closure
Authors: Jia Zhu, Honglei Zhou, Ethan Michael Gerhard, Senhao Zhang, Flor Itzel Parra Rodríguez, Taisong Pan, Hongbo Yang, Yuan Lin, Jian Yang, Huanyu Cheng
Journal: Bioactive Materials (2022)

The high demand for rapid wound healing has spurred the development of multifunctional and smart bioadhesives with strong bioadhesion, antibacterial effect, real-time sensing, wireless communication, and on-demand treatment capabilities. Bioadhesives with bio-inspired structures and chemicals have shown unprecedented adhesion strengths, as well as tunable optical, electrical, and bio-dissolvable properties. Accelerated wound healing has been achieved via directly released antibacterial and growth factors, material or drug-induced host immune responses, and delivery of curative cells. Most recently, the integration of biosensing and treatment modules with wireless units in a closed-loop system yielded smart bioadhesives, allowing real-time sensing of the physiological conditions (e.g., pH, temperature, uric acid, glucose, and cytokine) with iterative feedback for drastically enhanced, stage-specific wound healing by triggering drug delivery and treatment to avoid infection or prolonged inflammation. Despite rapid advances in the burgeoning field, challenges still exist in the design and fabrication of integrated systems, particularly for chronic wounds, presenting significant opportunities for the future development of next-generation smart materials and systems.
Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthma
Authors: Janet K. Jackman, Amy Stockwell, David F. Choy, Markus M. Xie, Peipei Lu, Guiquan Jia, Hong Li, Alexander R. Abbas, Paola G. Bronson, Wei-Yu Lin, Cecilia P.C. Chiu, Henry R. Maun, Merone Roose-Girma, Lucinda Tam, Juan Zhang, Zora Modrusan, Robert R. Graham, Timothy W. Behrens, Steven R. White, Ted Naureckas, Carole Ober, Manuel Ferreira, Radislav Sedlacek, Jiansheng Wu, Wyne P. Lee, Robert A. Lazarus, James T. Koerber, Joseph R. Arron, Brian L. Yaspan, Tangsheng Yi
Journal: Journal of Allergy and Clinical Immunology (2022)

Clinical studies of type 2 (T2) cytokine-related neutralizing antibodies in asthma have identified a substantial subset of patients with low levels of T2 inflammation who do not benefit from T2 cytokine neutralizing antibody treatment. Non-T2 mechanisms are poorly understood in asthma but represent a redefined unmet medical need.We sought to gain a better understanding of genetic contributions to T2-low asthma.We utilized an unbiased genome-wide association study of patients with moderate to severe asthma stratified by T2 serum biomarker periostin. We also performed additional expression and biological analysis for the top genetic hits.We identified a novel protective single nucleotide polymorphism at chr19q13.41, which is selectively associated with T2-low asthma and establishes Kallikrein-related peptidase 5 (KLK5) as the causal gene mediating this association. Heterozygous carriers of the single nucleotide polymorphisms have reduced KLK5 expression. KLK5 is secreted by human bronchial epithelial cells and elevated in asthma bronchial alveolar lavage. T2 cytokines IL-4 and IL-13 downregulate KLK5 in human bronchial epithelial cells. KLK5, dependent on its catalytic function, induces epithelial chemokine/cytokine expression. Finally, overexpression of KLK5 in airway or lack of an endogenous KLK5 inhibitor, SPINK5, leads to spontaneous airway neutrophilic inflammation.Our data identify KLK5 to be the causal gene at a novel locus at chr19q13.41 associated with T2-low asthma.
Addition of Coronary Artery Calcium Scores to Primary Prevention Risk Estimation Models—<i>Primum Non Nocere</i>
Authors: Robert J. Gallo, David L. Brown
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration
Authors: Xiongfa Ji, Hongwei Shao, Xiaohong Li, Muhammad Wajid Ullah, Guowen Luo, Ziyang Xu, Limin Ma, Xuecheng He, Zehua Lei, Qian Li, Xulin Jiang, Guang Yang, Yu Zhang
Journal: Biomaterials (2022)
Preferences for End-of-Life Care Among Patients With Terminal Cancer in China
Authors: Anli Leng, Elizabeth Maitland, Siyuan Wang, Stephen Nicholas, Kuixu Lan, Jian Wang
Journal: JAMA Network Open (2022)

In China, little is known about end-of-life (EOL) care preferences of patients with terminal cancer. Understanding these patients' treatment preferences is needed to improve patient-centered health care, better inform surrogates and medical staff about patient preferences, and enhance the quality of EOL care.
Changeable net charge on nanoparticles facilitates intratumor accumulation and penetration
Authors: Aziz Awaad, Hiroyasu Takemoto, Muneaki Iizuka, Koichi Ogi, Yuki Mochida, Abdul-Hackam Ranneh, Masahiro Toyoda, Makoto Matsui, Takahiro Nomoto, Yuto Honda, Kotaro Hayashi, Keishiro Tomoda, Tomoyuki Ohtake, Yutaka Miura, Nobuhiro Nishiyama
Journal: Journal of Controlled Release (2022)
USPSTF Report on Aspirin for Primary Prevention
Authors: Donald M. Lloyd-Jones
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Defining Normal
Authors: Alan R. Schroeder, Rebecca Dang
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Professional Courtesy
Authors: Daniel A. Pollyea
Journal: Annals of Internal Medicine (2022)

On Being a DoctorJune 2022Professional CourtesyDaniel A. Pollyea, MD, MSDaniel A. Pollyea, MD, MSDivision of Hematology, Department of Medicine, University of Colorado, Aurora, ColoradoSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-0392 Audio Reading - “Professional Courtesy” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Professional Courtesy” by Daniel A. Pollyea, MD, MS Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The e-mails land in my inbox with a near-audible thud; as soon as they are opened, I hear a clock begin to tick. Maybe the mother of an old friend from residency lives in my town and needs a second opinion on surgical options for her breast cancer. Or the uncle of a colleague from another institution was just diagnosed with a brain tumor and needs to be urgently seen. Maybe an endocrinologist in India has a question about his mother's myeloproliferative neoplasm. In any of these scenarios, some medical professional within six degrees of separation needs my help—what can ... Author, Article, and Disclosure InformationAffiliations: Division of Hematology, Department of Medicine, University of Colorado, Aurora, ColoradoCorresponding Author: Daniel A. Pollyea, MD, MS, University of Colorado Division of Hematology, Department of Medicine, 1665 Aurora Court, Aurora, CO 80045; e-mail, daniel.[email protected]edu.This article was published at Annals.org on 26 April 2022. PreviousarticleNextarticle Advertisement Audio Reading - “Professional Courtesy” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Professional Courtesy” by Daniel A. Pollyea, MD, MS Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics June 2022Volume 175, Issue 6Page: 903-904 ePublished: 26 April 2022 Issue Published: June 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Protein phosphatase 2Acα modulates fatty acid oxidation and glycolysis to determine tubular cell fate and kidney injury
Authors: Mengru Gu, Mengzhu Tan, Lu Zhou, Xiaoli Sun, Qingmiao Lu, Mingjie Wang, Hanlu Jiang, Yan Liang, Qing Hou, Xian Xue, Zhuo Xu, Chunsun Dai
Journal: Kidney International (2022)
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction
Authors: Jawad H. Butt, Pooja Dewan, Béla Merkely, Jan Belohlávek, Jarosław Drożdż, Masafumi Kitakaze, Silvio E. Inzucchi, Mikhail N. Kosiborod, Felipe A. Martinez, Sergey Tereshchenko, Piotr Ponikowski, Olof Bengtsson, Daniel Lindholm, Anna Maria Langkilde, Morten Schou, Mikaela Sjöstrand, Scott D. Solomon, Marc S. Sabatine, Chern-En Chiang, Kieran F. Docherty, Pardeep S. Jhund, Lars Køber, John J.V. McMurray
Journal: Annals of Internal Medicine (2022)

Background: Frailty may modify the risk−benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments. Objective: To investigate the efficacy of dapagliflozin according to frailty status, using the Rockwood cumulative deficit approach, in DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure). Design: Post hoc analysis of a phase 3 randomized clinical trial. (ClinicalTrials.gov: NCT03036124) Setting: 410 sites in 20 countries. Patients: Patients with symptomatic heart failure (HF) with a left ventricular ejection fraction of 40% or less and elevated natriuretic peptide. Intervention: Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy. Measurements: The primary outcome was worsening HF or cardiovascular death. Results: Of the 4744 patients randomly assigned in DAPA-HF, a frailty index (FI) was calculable in 4742. In total, 2392 patients (50.4%) were in FI class 1 (FI ≤0.210; not frail), 1606 (33.9%) in FI class 2 (FI 0.211 to 0.310; more frail), and 744 (15.7%) in FI class 3 (FI ≥0.311; most frail). The median follow-up time was 18.2 months. Dapagliflozin reduced the risk for worsening HF or cardiovascular death, regardless of FI class. The differences in event rate per 100 person-years for dapagliflozin versus placebo from lowest to highest FI class were −3.5 (95% CI, −5.7 to −1.2), −3.6 (CI, −6.6 to −0.5), and −7.9 (CI, −13.9 to −1.9). Consistent benefits were observed for other clinical events and health status, but the absolute reductions were generally larger in the most frail patients. Study drug discontinuation and serious adverse events were not more frequent with dapagliflozin than placebo, regardless of FI class. Limitation: Enrollment criteria precluded the inclusion of very high-risk patients. Conclusion: Dapagliflozin improved all outcomes examined, regardless of frailty status. However, the absolute reductions were larger in more frail patients. Primary Funding Source: AstraZeneca.
Annals Graphic Medicine - Dr. Mom: Bedtime Hack
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2022)

Web ExclusivesMay 2022Annals Graphic Medicine - Dr. Mom: Bedtime HackFREEGrace E. Farris, MDGrace E. Farris, MDUniversity of Texas, Austin, Texas (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G22-0020 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: University of Texas, Austin, Texas (G.E.F.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G22-0020.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Dell Medical School at the University of Texas in Austin, Texas. You can view her work at her website: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears monthly in Annals Graphic Medicine.This article was published at Annals.org on 26 April 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics May 2022Volume 175, Issue 5Page: W60-W61 ePublished: 26 April 2022 Issue Published: May 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
How Traditional Advance Directives Undermine Advance Care Planning
Authors: Catherine L. Auriemma, Helen O’Donnell, Tamar Klaiman, Julia Jones, Zoe Barbati, Eda Akpek, Scott D. Halpern
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Stress-Related Disorders of Family Members of Patients Admitted to the Intensive Care Unit With COVID-19
Authors: Timothy Amass, Lauren Jodi Van Scoy, May Hua, Melanie Ambler, Priscilla Armstrong, Matthew R. Baldwin, Rachelle Bernacki, Mansoor D. Burhani, Jennifer Chiurco, Zara Cooper, Hope Cruse, Nicholas Csikesz, Ruth A. Engelberg, Laura D. Fonseca, Karin Halvorson, Rachel Hammer, Joanna Heywood, Sarah Hochendoner Duda, Jin Huang, Ying Jin, Laura Johnson, Masami Tabata-Kelly, Emma Kerr, Trevor Lane, Melissa Lee, Keely Likosky, Donald McGuirl, Tijana Milinic, Marc Moss, Elizabeth Nielsen, Ryan Peterson, Sara J. Puckey, Olivia Rea, Sarah Rhoads, Christina Sheu, Wendy Tong, Pamela D. Witt, James Wykowski, Stephanie Yu, Renee D. Stapleton, J. Randall Curtis
Journal: JAMA Internal Medicine (2022)

The psychological symptoms associated with having a family member admitted to the intensive care unit (ICU) during the COVID-19 pandemic are not well defined.To examine the prevalence of symptoms of stress-related disorders, primarily posttraumatic stress disorder (PTSD), in family members of patients admitted to the ICU with COVID-19 approximately 90 days after admission.This prospective, multisite, mixed-methods observational cohort study assessed 330 family members of patients admitted to the ICU (except in New York City, which had a random sample of 25% of all admitted patients per month) between February 1 and July 31, 2020, at 8 academic-affiliated and 4 community-based hospitals in 5 US states.Having a family member in the ICU with COVID-19.Symptoms of PTSD at 3 months, as defined by a score of 10 or higher on the Impact of Events Scale 6 (IES-6).A total of 330 participants (mean [SD] age, 51.2 [15.1] years; 228 [69.1%] women; 150 [52.8%] White; 92 [29.8%] Hispanic) were surveyed at the 3-month time point. Most individuals were the patients' child (129 [40.6%]) or spouse or partner (81 [25.5%]). The mean (SD) IES-6 score at 3 months was 11.9 (6.1), with 201 of 316 respondents (63.6%) having scores of 10 or higher, indicating significant symptoms of PTSD. Female participants had an adjusted mean IES-6 score of 2.6 points higher (95% CI, 1.4-3.8; P < .001) than male participants, whereas Hispanic participants scored a mean of 2.7 points higher compared with non-Hispanic participants (95% CI, 1.0-4.3; P = .002). Those with graduate school experience had an adjusted mean score of 3.3 points lower (95% CI, 1.5-5.1; P < .001) compared with those with up to a high school degree or equivalent. Qualitative analyses found no substantive differences in the emotional or communication-related experiences between those with high vs low PTSD scores, but those with higher scores exhibited more distrust of practitioners.In this cohort study, symptoms of PTSD among family members of ICU patients with COVID-19 were high. Hispanic ethnicity and female gender were associated with higher symptoms. Those with higher scores reported more distrust of practitioners.
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
Authors: Joseph Therriault, Tharick A. Pascoal, Firoza Z. Lussier, Cécile Tissot, Mira Chamoun, Gleb Bezgin, Stijn Servaes, Andrea L. Benedet, Nicholas J. Ashton, Thomas K. Karikari, Juan Lantero-Rodriguez, Peter Kunach, Yi-Ting Wang, Jaime Fernandez-Arias, Gassan Massarweh, Paolo Vitali, Jean-Paul Soucy, Paramita Saha-Chaudhuri, Kaj Blennow, Henrik Zetterberg, Serge Gauthier, Pedro Rosa-Neto
Journal: Nature Aging (2022)

Abstract Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems. Using the topographical information from [ 18 F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals. We used PET-based Braak stage to model the trajectories of amyloid-β, phosphorylated tau (pTau) in cerebrospinal fluid (pTau 181 , pTau 217 , pTau 231 and pTau 235 ) and plasma (pTau 181 and pTau 231 ), neurodegeneration and cognitive symptoms. We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III–IV, followed by plateaus. Early Braak stages were associated with isolated memory impairment, whereas Braak stages V–VI were incompatible with normal cognition. In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-β positivity. Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management
Authors: Jennifer Deal, Julio C. Rojas
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal